August 2016August 2016
New Product - Fraxiparine
Fraxiparine (nadroparin calcium) is a low molecular weight heparin made by depolymerisation of standard heparin. It is a glycosaminoglycan with a mean molecular weight around 4,500 daltons. It possesses a high ratio of anti‑Xa activity to anti‑IIa activity between 2.5 to 4.0 compared to unfractionated heparin for which this ratio is one. Nadroparin has both immediate and prolonged antithrombotic action. Nadroparin exhibits a high-affinity binding to the plasma protein anti‑thrombin III (ATIII). This binding leads to an accelerated inhibition of factor Xa and to a lesser extent, factor IIa (Anti‑Xa:Anti‑IIa ratio of 3.6:1), which contributes to the antithrombotic potential of nadroparin. Fraxiparine is indicated for prophylaxis against deep vein thrombosis (DVT) associated with general or orthopaedic surgery and for treatment of DVT and in the prevention of clotting during haemodialysis. Fraxiparine is contraindicated in patients with: a history of thrombocytopenia with nadroparin; an increased risk of haemorrhage including those with bleeding disorders (except for disseminated intravascular coagulation not induced by heparin); active bleeding or organic lesions likely to bleed (such as active peptic ulceration), haemorrhagic cerebrovascular accident or infective endocarditis and severe renal failure (creatinine clearance < 30 mL/min) receiving treatment for DVT. Fraxiparine is available as 1900 IU/0.2 mL, 2850 IU/0.3 mL, 3800 IU/0.4 mL, 5700 IU/0.6 mL, 7600 IU/0.8 mL and 9500 IU/1 mL in single use prefilled glass syringe, packs of 2’s.
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au